Key Updates
EssilorLuxottica shares have reversed sharply, falling 4.26% to $165.10 after a July 30 Bloomberg report exposed escalating family infighting over Leonardo Del Vecchio's $46 billion legacy, undermining the recent relief rally. The stock has retraced the entire 4.01% advance recorded in the prior session and is again approaching the July 23 low of $161.50. Q2 revenue of €7.69 billion missed analyst expectations despite 8.7% constant-currency growth and near-doubling of Ray-Ban smartglasses sales, while Delfin shareholder conflicts persist with a stalled €10 billion buyout proposal.
Current Trend
The stock remains in a severe downtrend: YTD -38.83%, 6-month -35.15%, and 1-month +0.98%. The 5-day gain of +0.43% is marginal and insufficient to offset the broader bearish trajectory. The failed relief rally—rejected at $172.45 and reversing to $165.10—confirms that selling pressure resumes immediately upon negative catalysts. Near-term support rests at the July 23 low of $161.50; resistance is now established at $172.45.
Investment Thesis
The investment thesis is increasingly pressured by governance risk. Operationally, EssilorLuxottica demonstrates resilience through double-digit smartglasses growth and a strategic pivot toward integrated med-tech services via LensCrafters. However, the controlling family's public feud introduces material uncertainty over long-term strategic direction, capital allocation, and potential changes in the shareholder structure. Macroeconomic headwinds already constrained Q2 revenue, and the added governance overhang exacerbates the risk premium.
Thesis Status
The thesis has deteriorated. The prior relief rally was contingent on stabilization in operational performance and technical support holding near $161.50. The emergence of a high-profile family succession dispute on July 30 acts as a negative catalyst that overrides near-term product-cycle optimism. The status has shifted from cautiously stabilizing to actively deteriorating due to unresolved controlling-shareholder risk.
Key Drivers
- Family feud over Del Vecchio's $46 billion fortune threatening company stability (Bloomberg, July 30)
- Q2 revenue miss on global economic tumult; Ray-Ban smartglasses sales nearly doubled (Bloomberg, July 28)
- Delfin shareholder meeting conflict and stalled governance reforms (Reuters, June 30)
- LensCrafters med-tech ecosystem expansion in Exton, PA (PR Newswire, June 30)
Technical Analysis
Price action shows a failed relief rally. After bouncing from $161.50 on July 23 to $172.45 on July 29 (+6.8%), the stock reversed sharply to $165.10, a -4.26% drop. This rejection at higher levels reasserts the downtrend. The July 23 low of $161.50 represents critical near-term support; a decisive break below this level would open further downside. The 1-day decline of -2.10% on news-driven volume indicates renewed institutional selling pressure.
Bull Case
- Ray-Ban smartglasses sales nearly doubled in Q2, demonstrating category leadership and resilient demand in the high-margin eyewear technology segment. Source
- Q2 revenue increased 8.7% on a constant currency basis to €7.69 billion, indicating underlying operational resilience despite macro headwinds. Source
- LensCrafters launched its first Vision & Eye Health Center, expanding into integrated med-tech, surgical services, and wearable technology to capture higher-margin care revenue. Source
- The integration of Ray-Ban Meta and Nuance Audio within clinical settings creates a differentiated data-driven ecosystem of prevention and ongoing patient monitoring. Source
- The marginal 5-day gain of +0.43% and the recovery from the $161.50 low suggest some short-term stabilization above the June-July floor. Source
Bear Case
- The family infighting over the €40 billion legacy is threatening to destabilize the future of the eyewear giant, creating acute governance and succession risk that has directly triggered the latest sell-off. Source
- Second-quarter revenue missed analyst expectations at €7.69 billion, with management citing global economic tumult as a constraint on growth. Source
- The Delfin shareholder deadlock, including a stalled €10 billion stake buyout and competing proposals for asset divestitures, prolongs structural uncertainty over the controlling family's strategy. Source
- EssilorLuxottica shares have declined over the past year, and the governance uncertainty at Delfin adds another layer of complexity to the investment profile. Source
- The sharp -4.26% reversal from the July 29 high invalidates the recent relief rally, signaling that negative governance catalysts are overriding operational resilience and renewing selling pressure. Source